See the latest coronavirus and vaccine information. Learn about the Lancaster General Hospital Emergency Department expansion and related traffic changes.
Immunotherapy taps into the unique powers of the immune system to fight cancer. In 2015 the FDA approved two immunotherapy drugs—nivolumab (Opdivo®) and pembrolizumab (Keytruda®)—for the treatment of lung cancer. Nivolumab was approved for the treatment of squamous and non-squamous NSCLC. Pembrolizumab was approved for the treatment of PD-L1-positive NSCLC.
Immunotherapy has been shown to improve survival in patients with lung cancer compared to second line chemotherapy. These advancements would not have been possible without clinical trials.
Penn Medicine is leading the world in immunotherapy research. CAR-T therapy, developed by Penn Medicine, offers the world’s first gene-based cancer therapy to be approved by the FDA. It is a treatment that trains healthy cells to hunt down and eliminate cancer cells in patients with certain types of blood cancer. As part of Penn Medicine, Lancaster General Health provides patients with access to the most advanced treatment options and clinical trials. Learn more about immunotherapy at Penn Medicine.
Find our contact forms and phone numbers or give feedback on a recent experience using Care to Share.
View test results, schedule appointments, or request prescription refills from the convenience of your computer or mobile device.
Learn about health system news and meet new providers in Progress Notes, Lancaster General Health's provider newsletter.
Want to make a payment without a MyLGHealth account? Click the "Pay as Guest" button below.